Literature DB >> 19324529

Cannabis use and age of diagnosis of schizophrenia.

Gisela Sugranyes1, Itziar Flamarique, Eduard Parellada, Immaculada Baeza, Javier Goti, Emilio Fernandez-Egea, Miquel Bernardo.   

Abstract

BACKGROUND AND OBJECTIVES: Observational studies have reported earlier onset of psychosis in schizophrenic patients with a history of cannabis use. Earlier age of onset of schizophrenia has been associated with a poorer outcome. We aimed to examine whether cannabis use determined an earlier onset of schizophrenia in a sample of first episode patients, in an area with one of Europe's highest rates of cannabis use.
METHODS: 116 subjects with first episode psychosis and subsequent diagnosis of schizophrenia (after a 12-month follow-up) were included Age at first antipsychotic treatment (A1T) was used as proxy for age of psychosis onset, and acted as dependent variable for the statistical analysis. Cannabis use was evaluated retrospectively, and divided into three groups according to peak frequency (never, sporadic/frequent, daily).
RESULTS: 46 (39.7%) subjects had never used cannabis, 23 (19.9%) had done so sporadically/frequently, and 47 (40.5%) daily. A1T differed between the three groups (mean, in years and [SD]: 27.0 [4.94]; 25.7 [4.44] and 24.5 [4.36]; p=0.033) and diminished as cannabis use increased (linear tendency; p=0.009). Post-hoc analysis showed that cannabis use (irrespective of frequency) was significantly associated with decrease in A1T (p=0.033), as shown by the first contrast [1 -1/2 -1/2]. Post-hoc contrast showed that cannabis users had a significantly lower age of onset of psychosis (mean decrease, in years: 1.93; CI (confidence interval) 95%: 0.17-3.70; p=0.033).
CONCLUSIONS: Cannabis use was significantly associated with a decrease in age of onset of schizophrenia. Age of onset of the disease correlated with frequency of cannabis use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19324529     DOI: 10.1016/j.eurpsy.2009.01.002

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  12 in total

1.  Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis.

Authors:  Juan A Galvez-Buccollini; Ashley C Proal; Veronica Tomaselli; Melissa Trachtenberg; Cristinel Coconcea; Jinsoo Chun; Theo Manschreck; Jerry Fleming; Lynn E Delisi
Journal:  Schizophr Res       Date:  2012-06-21       Impact factor: 4.939

2.  [Managing the use of cannabis in a young population in primary care].

Authors:  Agustín Madoz-Gúrpide; Enriqueta Ochoa Mangado
Journal:  Aten Primaria       Date:  2011-02-20       Impact factor: 1.137

Review 3.  Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models.

Authors:  Daniel T Malone; Matthew N Hill; Tiziana Rubino
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Authors:  Miquel Bioque; Borja García-Bueno; Karina S Macdowell; Ana Meseguer; Pilar A Saiz; Mara Parellada; Ana Gonzalez-Pinto; Roberto Rodriguez-Jimenez; Antonio Lobo; Juan C Leza; Miguel Bernardo
Journal:  Neuropsychopharmacology       Date:  2013-07-04       Impact factor: 7.853

Review 5.  Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: implications for neuropsychiatric pathology.

Authors:  Roger Hudson; Walter Rushlow; Steven R Laviolette
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

6.  Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.

Authors:  Antonio Ortega-Alvaro; Auxiliadora Aracil-Fernández; María S García-Gutiérrez; Francisco Navarrete; Jorge Manzanares
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

Review 7.  Epigenetic mediation of environmental influences in major psychotic disorders.

Authors:  Bart P F Rutten; Jonathan Mill
Journal:  Schizophr Bull       Date:  2009-09-25       Impact factor: 9.306

8.  Screening for substance use disorders in first-episode psychosis: implications for readmission.

Authors:  Albert Batalla; Clemente Garcia-Rizo; Pere Castellví; Emili Fernandez-Egea; Murat Yücel; Eduard Parellada; Brian Kirkpatrick; Rocío Martin-Santos; Miguel Bernardo
Journal:  Schizophr Res       Date:  2013-03-19       Impact factor: 4.939

9.  Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.

Authors:  Eva M Marco; María S García-Gutiérrez; Francisco-Javier Bermúdez-Silva; Fabricio A Moreira; Francisco Guimarães; Jorge Manzanares; María-Paz Viveros
Journal:  Front Behav Neurosci       Date:  2011-10-05       Impact factor: 3.558

10.  Cannabis and schizophrenia spectrum disorders: a review of clinical studies.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse
Journal:  Indian J Psychol Med       Date:  2009-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.